The effect of 0.05% Cyclosporine A eyedrops in patients after cataract surgery
| ISRCTN | ISRCTN10173448 |
|---|---|
| DOI | https://doi.org/10.1186/ISRCTN10173448 |
| ClinicalTrials.gov (NCT) | Nil known |
| Clinical Trials Information System (CTIS) | Nil known |
| Protocol serial number | Nil known |
| Sponsor | Pusan National University Yangsan Hospital |
| Funder | Pusan National University Yangsan Hospital |
- Submission date
- 28/03/2020
- Registration date
- 06/04/2020
- Last edited
- 12/01/2021
- Recruitment status
- No longer recruiting
- Overall study status
- Completed
- Condition category
- Eye Diseases
Plain English summary of protocol
Background and study aims
Cataracts are when the lens of your eye, a small transparent disc, develops cloudy patches. Cataract surgery involves replacing the cloudy lens inside the eye with an artificial one.
The Meibomian glands along the rims of the eyelid produce meibum, an oily substance that prevents evaporation of the eye's tear film. Meibomian gland dysfunction (MGD) often occurs after cataract surgery.
Cyclosporine A (CsA) eye drops are a new treatment for MGD and dry eye syndrome after cataract surgery. The usual treatment is with Carboxymethyl cellulose (CMC) eye drops.
Who can participate?
Adult cataract patients with normal lid position and closure and not suffering from any ocular diseases.
What does the study involve?
Participants will be randomly allocated to receive 0.05% CsA or 0.5% Carboxymethyl cellulose (CMC) over three months following cataract surgery. Subjective and objective assessments are performed in each preoperative and postoperative visit.
What are the possible benefits and risks of participating?
When participating in the study, there might be no risks or benefits for patients. This is a controlled study comparing the group with and without the use of specific eye drops that are commercially available and have clinical safety. There is no direct benefit when the patient participates in the study.
Where is the study run from?
Department of Ophthalmology, Pusan National University School of Medicine, Yangsan (South Korea)
When is the study starting and how long is it expected to run for?
April 2019 to November 2019
Who is funding the study?
Pusan National University Yangsan Hospital (South Korea)
Who is the main contact?
Dr Min Seung Min Seung, kangminseung91@gmail.com
Contact information
Scientific
Pusan National University School of Medicine
20-Geumo-ro
Mulgeum-eup
Yangsan
50612
Korea, South
 ORCID ID |
0000-0001-5026-4117 |
|---|---|
| Phone | +82 55-360-1447 |
| kangminseung91@gmail.com |
Study information
| Primary study design | Interventional |
|---|---|
| Study design | Prospective randomized double-masked comparative clinical trial |
| Secondary study design | Randomised parallel trial |
| Study type | Participant information sheet |
| Scientific title | Efficacy of 0.05% Cyclosporine A on the lipid layer and meibomian gland after cataract surgery: a randomized, double-masked study |
| Study objectives | 0.05% cyclospoine A might improve MGD dysfunction and dry eye syndrome by comparison to 0.5% carboxymethyl cellulose after cataract surgery. |
| Ethics approval(s) | Approved 04/04/2019, Pusan National University Yangsan Hospital Institutional Review Board (#20 Geumo-ro, Mulgeum-eup, Yangsan 50612, South Korea; +82-55-360-3854; pnuyhirb@gmail.com), ref: 05-2019-049 |
| Health condition(s) or problem(s) studied | Dry eye syndrome, meibomian gland dysfunction |
| Intervention | Eligible patients are randomized using the random number method into two treatment groups. The first group will use 0.05% CsA ophthalmic emulsion (Restasis®, Allergan Inc., Irvine, CA) twice daily over three months following cataract surgery. The second group receive standard postoperative treatment with 0.5% carboxymethyl cellulose (CMC) (Refresh plus®, Allergan Inc., Irvine, CA). |
| Intervention type | Drug |
| Phase | Not Applicable |
| Drug / device / biological / vaccine name(s) | 0.05% CsA ophthalmic emulsion (Restasis®, Allergan Inc., Irvine, CA); 0.5% carboxymethyl cellulose (CMC) (Refresh plus®, Allergan Inc., Irvine, CA) |
| Primary outcome measure(s) |
At baseline and three months. |
| Key secondary outcome measure(s) |
none |
| Completion date | 30/11/2019 |
Eligibility
| Participant type(s) | Patient |
|---|---|
| Age group | Adult |
| Sex | All |
| Target sample size at registration | 50 |
| Total final enrolment | 50 |
| Key inclusion criteria | Adult cataract patients with normal lid position and closure and not suffering from any ocular diseases |
| Key exclusion criteria | 1. Patients who had used topical anti-inflammatory, antibiotic, or other medication during the previous 90 days before surgery 2. Eyes with a history of trauma, ocular surgery, laser or systemic treatment known to affect tear secretion, autoimmune disease, current use of contact lenses, and/or history of slit-lamp evidence of eye surface disorders |
| Date of first enrolment | 04/04/2019 |
| Date of final enrolment | 31/05/2019 |
Locations
Countries of recruitment
- Korea, South
Study participating centre
20-Geumo-ro
Mulgeum-eup
Yang San
50612
Korea, South
Results and Publications
| Individual participant data (IPD) Intention to share | No |
|---|---|
| IPD sharing plan summary | Data sharing statement to be made available at a later date |
| IPD sharing plan | The current data sharing plans for this study are unknown and will be available at a later date |
Study outputs
| Output type | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
|---|---|---|---|---|---|
| Results article | results | 11/01/2021 | 12/01/2021 | Yes | No |
| Participant information sheet | Participant information sheet | 11/11/2025 | 11/11/2025 | No | Yes |
| Protocol file | 15/05/2020 | No | No |
Additional files
- ISRCTN10173448_PROTOCOL.pdf
- uploaded 15/05/2020
Editorial Notes
12/01/2021: Publication reference added.
15/05/2020: Uploaded protocol (not peer reviewed) as an additional file.
06/04/2020: Trial’s existence confirmed by Pusan National University Yangsan Hospital Institutional Review Board.
